This Is What A No Deal Brexit Could Look Like For The Pharma & Devices Sector
Today’s publication (August 23rd 2018) of a range of documents by the UK’s Department for Exiting the European Union (DExEU) finally outlines what the UK’s thinking is on a range of issues. There has been much speculation and conjecture about...
Be Prepared For A No Deal Brexit
“Be Prepared” – Robert Baden Powell’s now-famous motto for the Scouting movement seems to be an apt aphorism when considering the possibility of a ‘no deal’ Brexit. Events and machinations within the UK Government now make the likelihood of such...
Blog: Brexit Pharma Update – The EMA Survey
The results of The European Medicines Agency Brexit preparedness survey, released in July 2018, show that the majority of Marketing Authorisation Holders (MAH’s) are taking steps to make the necessary changes to their marketing authorisations.
Packing Up & Moving – The EMA in Amsterdam.
The transfer of a manufacturing process or technology from one plant to another within a company can be an arduous process. It involves careful consideration of the impact to the existing site and a rigorous selection process to ensure that...
The Explainer: The Backstop
The difficult issue of the ‘Backstop’ has held up Brexit talks and might prove to be the undoing of a possible deal. But what actually is the ‘Backstop’? What does it mean and what purpose does it serve? In this...
‘Is Time Running Out?’ – The Sixth Acorn Regulatory Brexit Whitepaper
The course of Brexit has been filled with dramatic twists and unexpected happenings. The resignations of David Davis, Suella Braverman, Steve Baker and Boris Johnson have thrown the UK’s plans into disarray. While many of us did expect the Irish...
Uncertainty Abounds – How Customs Issues Are Now Dominating Brexit
There has been much spoken and written about Brexit since our last whitepaper, yet very little has progressed. The issue dogging the talks, that of the Irish border, has caused negotiations to move much like a tortoise when the pace...
Brexit and MAH Responsibilities – 5 Critical Points To Consider
The spectre of a ‘no deal’ Brexit looms large in the minds of life science professionals. What impact will this have for the Marketing Authorisation Holders? In this blog, we look at some of the key areas that will affect...
Acorn Regulatory NewsBrexitMarie CarrollMarketing Authorisation HoldersPharmaceuticalRegulatory Strategy
Focus on Variations
Acorn Regulatory’s pharmaceutical regulatory affairs consultants are experts in the sector. Every day our team members are working on behalf of clients to ensure that their variations are completed in as timely a manner as possible. Members of our team...
Brexit: The Need to Consider the Implications for the Patient
In this blog Brian Cleary looks at how different sides in the Brexit debate are not focusing on the needs of the patient when considering the future trading relationship between the UK and the EU.
